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Abstract:
While consumers’ health cognition and behavior are likely formed
through multiple influences, the current study focused on the effects of
exposure to specific content elements in direct-to-consumer advertising. The
study revealed that consumers’ exposure to the American Psychiatric
Association’s (APA) diagnostic guideline has potential to reduce their
perceived lifetime risk of depression and intention to consult a health
professional to discuss the health issue. The study further revealed when an
antidepressant ad mentioned a long list of symptoms, exposure to the
diagnostic guideline reduced risk perception and consultation intention
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significantly, whereas in the presence of a short list of symptoms, the APA
guideline had minimal impact.

Introduction
A large body of research shows direct-to-consumer (DTC)
prescription drug advertising has strong potential to influence
consumers’ health cognition and behavior. For instance, Iizuka and Jin1
reported the pharmaceutical industry’s DTC advertising expenditure
predicted an overall increase in consumer visits to doctors’ offices.
Similarly, Donohue and Berndt2 found the industry expenditure on DTC
antidepressant advertising led to an increase in the number of patient
requests for antidepressant treatment. When doctors refuse to
prescribe the requested drugs, patients tend to be dissatisfied and
insist on prescriptions for the drugs they saw from the
advertisements.3
Although the literature suggests DTC advertising has power to
spur the expansion of a drug brand or category, research has
predominantly focused on revealing how consumers ’ overall exposure
to a category of DTC advertising influences their beliefs, attitudes and
behavior regarding health issues. There is a paucity of research
attributing such cognitive and behavioral effects to consumer exposure
to specific content elements strategically placed in pharmaceutical ads.
Without research accounting for how consumers process and respond
to specific information categories in prescription drug ads, the
literature would present limited insights for the practice of DTC
advertising. The current study addresses this limitation by exploring
how exposure to specific categories of information in DTC ads
influences consumer perception of diseases.
Considering depression is increasingly prevalent among young
adults and consumer socialization begins at early life stages,5 the
current study is designed to explore how college students ’ perception
of clinical depression is influenced by the information DTC
antidepressant advertisements present regarding the symptoms of
clinical depression. More specifically, we expect college students’
estimation of their lifetime risk of depression and intention to consult a
health professional to discuss the health issue will be influenced by:
(1) the number of depression symptoms listed in the ad; (2) the type
of depression symptoms mentioned in the ad; and (3) whether the ad
4
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provides a guideline about the way consumers should use the
symptom information to assess their health appropriately.
Of many potentially important diseases, the current study
focuses on depression for the reason that although antidepressants are
one of the most heavily advertised prescription drug categories in the
DTC market,6 depression remains largely under-diagnosed and undertreated.7 This study will illuminate how antidepressant ads can be used
to influence consumer perception of the future risk of depression.
Considering high risk perception has potential to spur preventive and
remedial health behavior,8 the findings of this study will produce
insights into how advertising practitioners can use DTC advertising in
an effective and socially responsible way to expand the antidepressant
market and help reduce the under-treatment of depression.

Theoretical Framework
Information on the symptoms of a disease frequently appears in
DTC advertising. Antidepressant ads, for instance, typically present the
symptoms of clinical depression, such as sleep disorders and difficulty
with thinking. However, the ads present such symptoms in a variety of
ways. For example, after listing a wide range of depression symptoms,
an ad for Zoloft states that to be considered indicative of clinical
depression, the symptoms must interfere with one ’ s daily life and last
each day over a two-week period. This instruction is equivalent to the
American Psychiatric Association’s (APA)9 guideline for the accurate
diagnosis of depression. In comparison, an ad for Effexor XR mentions
only one symptom, ‘wanting to be alone’, without further symptomrelated information.
Differences in the way antidepressant ads present the
symptoms of depression are expected to influence consumer
perception of the future risk of depression. The principle of
representativeness heuristic10 suggests consumers will report a higher
subjective risk of depression as they perceive their life experiences to
be more similar to the experiences of typical depression patients.
Information on the symptoms of depression has potential to influence
risk estimation by altering consumers ’ mental prototype of depression
patients,11 which in turn will affect the perceived similarity between
their own and the typical patients ’ life experiences. The power of
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symptom information to influence risk perception is rooted in
consumers ’ tendency to heuristically assume the presented symptoms
represent the population of depression symptoms.10
The principle of representativeness heuristic leads to the
expectation that consumer perception of the lifetime risk of depression
will be influenced by the number of depression symptoms listed in an
antidepressant ad and exposure to an APA-type diagnostic guideline.
The APA9 suggests that, to be considered indicative of clinical
depression, one’s experiences of the symptoms of depression should
last nearly every day over a two-week period. Therefore, the guideline
does not permit the inference that one is depressed based on
observation of the symptoms for a day or a few days. For this reason,
exposure to the guideline has potential to reduce the perceived
lifetime risk of depression by decreasing the degree to which
individuals perceive their life experiences to resemble those of typical
depression patients.
However, exposure to the APA guideline will have stronger
effects on risk perception when the ad presents a long list of
symptoms, compared to when fewer symptoms are listed. This is
because, given the guideline that observation of symptoms for a few
days does not indicate depression, exposure to a large amount of
symptom information would further corroborate one’s initial judgment
that the future risk of depression would be low.11 In contrast, the APA
guideline would have significantly reduced impact on risk perception
when a smaller amount of symptom information is presented.
Therefore, we hypothesize that when the ad presents a long list
of symptoms, exposure to the APA guideline will significantly decrease
the perceived lifetime risk of depression. In contrast, in the presence
of a short list of symptoms, the APA guideline will have minimal impact
on risk perception (H1). Once formed, risk perception is a strong
determinant of consumer engagement in preventive and remedial
health behaviors.8,12,13 Therefore, we hypothesize that the APA
guideline and the number of symptoms will influence consumer
intention to consult a health professional to discuss depression in the
same pattern as they affect risk perception (H2).
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Similar to exposure to the APA guideline, the type of depression
symptoms presented in the ad will also interact with the number of
symptoms to influence risk perception. Following Menon et al,11 the
current study categorizes the symptoms of depression into: (a)
common symptoms, defined as the symptoms that subjects experience
relatively frequently in their lives; and (b) uncommon symptoms,
namely the symptoms subjects experience less frequently.
Exposure to common symptoms would lead to the judgment
that one’s own life experiences resemble those of typical depression
patients, and therefore has potential to raise the perceived risk of
depression, whereas uncommon symptoms would have the opposite
effects.11 In addition, the effects of symptom type (that is, common
versus uncommon) will be stronger when the ad presents a long list of
symptoms than when fewer symptoms are listed. This is because, once
exposed to a particular type of symptoms, receiving more symptoms
of the same category will corroborate one’s initial judgment of the
future risk of depression.11
Therefore, we hypothesize that when the ad presents a long list
of symptoms, exposure to common symptoms will result in a
significantly higher perceived lifetime risk of depression than exposure
to uncommon symptoms. In contrast, with a short list of symptoms,
exposure to common versus uncommon symptoms will produce a
minimal difference in risk perception (H3). We further expect the
number and type of symptoms to have the same interactive effects on
consultation intention (H4).

Method
Design
A 2 (number of symptoms: two versus five) × 2 (exposure to
the APA guideline: present versus absent) × 2 (type of symptoms:
common versus uncommon) between-subjects design was employed
with a non-factorial control group. Because a moderate correlation was
expected between risk perception and consultation intention,
multivariate analysis of variance (MANOVA) was used as the main
method of hypotheses testing. Follow-up tests of simple effects were
conducted for exploratory purposes.
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Subjects and Procedure
A total of 318 undergraduates enrolled in introductory
advertising courses at a southern state university participated in return
for course credit. Fifteen subjects reported they had experienced
clinical depression. Because the question to measure the perceived
lifetime risk of depression (that is, ‘what are the chances that you will
suffer from depression during your lifetime?’) was considered
irrelevant to those who had already experienced depression, the 15
subjects were deleted from further analysis. Of the remaining 303
subjects, 66.7 percent were females, and the average age was 20.23
(SD= 2.16). The majority were whites (74.3 percent), followed by
Hispanics (10.6 percent), Asian Americans (7.6 percent), and African
Americans (5.6 percent).
Sessions were conducted in a laboratory. Subjects participated
in groups of 5 to 25. To differentiate clinical depression from
temporary mood swings, subjects were instructed that ‘clinical
depression is defined in this project as a form of medical illness that
may require doctor’s intervention for treatment’. Then subjects were
randomly assigned to the nine experimental groups. It took
approximately 15 min to complete the instrument. Upon completion of
the instrument, subjects were thanked and debriefed.

Stimulus
A pretest was conducted to select the five common and
uncommon symptoms of depression. A total of 29 symptoms were
compiled from widely cited measures of depression.9,14 Subjects (N=
45) reported on a seven-point scale (1 =never, 7 =very frequently)
how frequently they experienced the symptoms. The five common
symptoms selected were sleep disorders, feeling tired for no reason,
restlessness, difficulty with thinking and inability to make decisions.
The five uncommon symptoms were feeling hopeless about the future,
feeling one ’ s life is empty, inability to enjoy the things one used to
do, feeling guilty or worthless, and having acquaintances notice that
one is restless.
The number and type of depression symptoms and exposure to
the APA guideline were manipulated between subjects by exposing
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them to different versions of information about a fictitious
antidepressant brand. Similar to Davis,15 the study was introduced as
a copy-test for a new advertising campaign for an antidepressant
brand recently released by an unnamed pharmaceutical company.
Accordingly, the stimulus was disguised as the body copy of the
advertisement. The following is the stimulus assigned to the group that
received two common symptoms of depression with the APA guideline.
The copy was equal across the eight treatment groups except for the
italicized part, where manipulations occurred.
You have trouble sleeping through the night … You get tired for
no reason … If these last nearly every day for two weeks, they are
symptoms of depression. Some may say it’s ‘just in your head.’ But
depression is a serious illness with real medical causes. While the
causes are unknown, depression is related with an imbalance of
chemicals in the brain. Clinical studies prove that Celsta can effectively
correct this imbalance and relieve symptoms of depression. Celsta is
not for everyone. It is approved for adults 18 and over. People taking
MAOIs should not take Celsta. Side effects may include dry mouth,
dizziness, insomnia, delayed ejaculation, diarrhea, anorexia, and
sleepiness. Celesta is a prescription drug. Talk to your doctor about
Celsta. Get a free educational DVD about depression and Celsta by
calling 1-800-6-Celsta, or visiting YouNeedNewLife.com .

Measures
Type of Symptoms (Common versus Uncommon)
The type of symptoms was manipulated between subjects by
assigning them to common or uncommon symptoms of depression.
Although the number of symptoms listed in the stimulus varied
between two and five, for the purpose of checking the manipulation,
subjects reported their experiences with the five common or
uncommon symptoms after completing the dependent measures.
The manipulation was checked separately for the subjects who
received the APA guideline (n = 137) and those without the guideline
(n = 136). In response to the five common or uncommon symptoms,
subjects without the APA guideline (n = 137) answered the following
question on a seven-point scale (1 = never, 7 = very frequently): ‘In
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your life these days, how often do you have the following feelings /
experiences?’ Responses to the five symptoms were averaged into a
symptom frequency index.
For the same common or uncommon symptoms, subjects
exposed to the APA guideline (n =136) answered the following
question on a seven-point scale (1= not likely at all, 7 =very likely):
‘Looking back on your life these days, how likely would it be that you
have the following feelings / experiences nearly every day for a given
two-week period? ’ Responses to the five symptoms were averaged
into a symptom likelihood index.

Perceived Lifetime Risk of Depression
Subjects answered in percentage the following single-item
question: ‘What are the chances that you will suffer from depression
during your lifetime?’ The non-factorial control group rated the lifetime
risk to be 19.17 on the average (SD =18.88). Notably, males and
females did not significantly differ in their risk perception (Mmales =
17.83, SD = 23.53; Mfemales = 20.06, SD = 15.74), while
epidemiological studies indicate the actual lifetime risk is
approximately 25 percent for women and 12 percent for men.16,17

Intention for Consultation
Subjects indicated on a seven-point scale (1= strongly disagree,
7= strongly agree) their agreement with the following statement: ‘If
the University Health Services offered free consultation about
depression, I would intend to participate to know more about
depression or Celsta’, similar to the single-item scale used by Raghubir
and Menon.18 Because the non-factorial control group was not
exposed to any antidepressant brand, the fictitious brand name was
replaced with ‘ antidepressants ’ in the statement for the group. Males
and females did not differ in their consultation intention (Mmales = 3.17,
SD = 1.53; Mfemales = 3.37, SD = 1.54), a result in sync with a minimal
gender difference in risk perception.
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Perceived Symptom Representativeness
A vital assumption of the principle of representative heuristic is
that consumers assume the presented symptoms represent the
population of depression symptoms.10 To check if this assumption is
valid in the sample, subjects checked on a seven-point scale (1 = not
representative at all, 7 = highly representative) how representative a
series of experiences were of the symptoms of depression. The
experiences were the depression symptoms used to manipulate
symptom type. Subjects without the APA guideline (n = 136) reported
their judgments on the five common or uncommon symptoms.
Subjects with the APA guideline (n = 137) reported how representative
it was to experience the five common or uncommon symptoms‘ nearly
every day for a given two-week period’. Responses were averaged into
a symptom representativeness index.

Results
Manipulation Check
For the subjects with no exposure to the APA guideline, the
symptom frequency index was submitted to a 2 (number of
symptoms: two versus five) × 2 (type of symptoms: common versus
uncommon) factorial ANOVA. As desired, the type of symptoms had a
significant main effect on the frequency index [Mcommon = 3.37, SD =
1.14; Muncommon = 2.27, SD = 1.10, F(1, 132) = 33.09, P < 0.001, 𝑛𝑝2 =
0.20], while no other significant main or interaction effect was
observed.
For the subjects exposed to the APA guideline, we conducted a 2
(number of symptoms: two versus five) × 2 (type of symptoms:
common versus uncommon) factorial ANOVA on the symptom
likelihood index. The results indicated that the type of symptoms had a
significant main effect on the likelihood index [Mcommon = 2.55, SD =
1.25; Muncommon = 1.59, SD = 0.68, F(1, 133) = 32.20, P < 0.001, 𝑛𝑝2 =
0.20]). As desired, no other significant main or interaction effect was
observed, implying the manipulation was successful.
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Symptom Representativeness
To test whether consumers assume the presented symptoms
represent the population of depression symptoms regardless of
symptom type and exposure to the APA guideline, the symptom
representativeness index was submitted to a 2 (number of symptoms:
two versus five) × 2 (exposure to the APA guideline: presence versus
absent) × 2 (type of symptoms: common versus uncommon) factorial
ANOVA. The results showed exposure to the APA guideline did not
have a significant main effect on the representativeness index [MAPA =
4.64, SD = 1.89; MnoAPA = 4.50, SD = 1.65, F(1, 264) = 5.82, P =
0.45]. However, symptom type had a significant main effect [Mcommon =
4.05, SD= 1.68; Muncommon = 5.06, SD=1.73, F(1, 264) = 24.17, P <
0.001], violating a vital assumption of the principle of
representativeness heuristic. This led to the expectation that H3 and
H4 might not be supported. No other main or two-way interaction
effects were significant. However, the three-way interaction was
significant [F(1, 264) = 6.45, P = 0.01].

H1 and H2
Hypotheses 1 and 2 were designed to examine the interactive
effects of the number of symptoms and exposure to the APA guideline
on subjects’ perceived lifetime risk of depression and consultation
intention. The two hypotheses were tested by conducting a 2 (number
of symptoms: two versus five) × 2 (exposure to the APA guideline:
present versus absent) × 2 (type of symptoms: common versus
uncommon) MANOVA on risk perception and consultation intention.
The assumption of homogeneous variance-covariance matrices was
satisfied [Box’s M= 29.18, F(21, 245417) = 1.36, P = 0.13].
The MANOVA results revealed the number of symptoms ×
exposure to the APA guideline interaction was significant (see Table 1),
indicating the effects of the APA guideline on risk perception and
consultation intention were moderated by the amount of symptom
information. The three-way interaction was not significant, indicating
the significance of the two-way interaction did not depend on the type
of symptoms.
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The MANOVA results would be invalidated if the number of
symptoms × exposure to the APA guideline interaction had differential
effects on risk perception and consultation intention. If the effects
significantly differed, conducting ANOVAs for testing H1 and H2
separately would be more appropriate than using a MANOVA for
testing the two hypotheses simultaneously. To check this possibility, a
four-way mixed MANOVA was designed, entering the three
independent variables as between-subjects factors and risk perception
and consultation intention as a within-subjects factor. For
comparability, scores on risk perception and consultation intention
were Z-transformed.
As Table 2 shows, the three-way interaction of exposure to the
APA guideline, number of symptoms and the within-subject factor was
not significant. This ruled out the possibility that the number of
symptoms × the APA guideline interaction might have differential
effects on risk perception and consultation intention. Therefore, followup ANOVAs were not necessary.
Analyses of simple effects further revealed the interaction
largely occurred in such a pattern as specified in H1 and H2. Among
subjects who received common symptoms, when the ad listed two
symptoms, exposure to the APA guideline did not produce a significant
difference in risk perception [t(62.99) = 0.32, P = 0.75, Mtwo-commonnoAPA = 27.52, SD = 25.98; Mtwo-common-APA = 29.53, SD = 25.47] or
consultation intention [t(294) = 1.57, P = 0.12, Mtwo-common-noAPA = 2.15,
SD = 1.28; Mtwo-common-APA = 2.72, SD = 1.75]. In contrast, when five
symptoms were presented, the APA guideline significantly reduced risk
perception [t(62.35 = 2.45, P = 0.02, Mfive-common-noAPA = 33.82, SD =
25.08; Mfive-common-APA = 20.19, SD = 20.77] and consultation intention
[t(294)=2.07, P = 0.04, Mfive-common-noAPA = 2.73, SD = 1.35; Mfive-commonAPA = 2.00, SD = 1.35].
A similar pattern was observed among subjects who received
uncommon symptoms. When the ad presented two symptoms,
exposure to the APA guideline did not significantly reduce risk
perception [t(56.59)= 1.10, P = 0.28, Mtwo-uncommon-noAPA = 19.89, SD =
18.47; Mtwo-uncommon-APA = 25.91, SD = 26.32] or consultation intention
[t(294) = 1.05, P = 0.29, Mtwo-uncommon-noAPA = 2.22, SD = 1.58; Mtwouncommon-APA = 1.85, SD = 1.35]. In contrast, when five symptoms were
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presented, the APA guideline significantly reduced consultation
intention [t(294) = 2.73, P = 0.007, Mfive-uncommon-noAPA = 3.15, SD =
1.58; Mfive-uncommon-APA = 2.19, SD = 1.43]. The APA guideline reduced
risk perception, but the reduction did not reach statistical significance [
t(64.31) =1.11, P =0.27, Mfive-uncommon-noAPA = 26.33, SD=22.47; Mfiveuncommon-APA =20.64, SD =19.98].

H3 and H4
Hypotheses 3 and 4 were designed to examine the effects of the
number of symptoms and the type of symptoms on perceived lifetime
risk of depression and consultation intention. Table 1 shows the
number × type of symptoms interaction was not significant, indicating
the effects of symptom type on the two dependent variables did not
depend on the amount of symptom information. Therefore, H3 and H4
were not supported. Table 1 also shows the three-way interaction was
not significant, implying the non-significance of the number × type of
symptoms interaction did not depend on whether subjects received the
APA guideline or not. Further, the effects of the number × type of
symptoms interaction were not moderated by the within-subject factor
(see Table 2), indicating the two-way interaction had equivalent
effects on risk perception and consultation intention.
Analyses of simple effects also revealed the effects of symptom
type on risk perception and consultation intention were equivalent
whether the ad presented two or five symptoms. Among subjects with
no exposure to the APA guideline, when the ad presented two
symptoms, exposure to common symptoms did not produce higher
risk perception [t(57.06) = 1.40, P = 0.17, Mtwo-common-noAPA = 27.52, SD
= 25.98; Mtwo-uncommon-noAPA = 19.89, SD = 18.47] or stronger
consultation intention [t(294) = 0.19, P = 0.85, Mtwo-common-noAPA =
2.15, SD = 1.28; Mtwo-uncommon-noAPA = 2.22, SD = 1.58] than exposure
to uncommon symptoms. Similarly, when five symptoms were
presented, the type of symptoms did not lead to a significant
difference in risk perception [t(63.24) = 1.28, P = 0.21, Mfive-commonnoAPA = 33.82, SD = 25.08; Mfive-uncommon-noAPA = 26.33, SD = 22.47] or
consultation intention [t(294) = 1.18, P = 0.24, Mfive-common-noAPA = 2.73,
SD = 1.35; Mfive-uncommon-noAPA = 3.15, SD = 1.58].
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Among subjects who received the APA guideline, when the ad
presented two symptoms, subjects exposed to common symptoms did
not report a higher risk perception [t(63.00) = 0.56, P = 0.58, Mtwocommon-APA = 29.53, SD = 25.47; Mtwo-uncommon-APA = 25.91, SD = 26.32],
but reported stronger consultation intention [t(294) = 2.41, P = 0.02,
Mtwo-common-APA = 2.72, SD = 1.75; Mtwo-uncommon-APA = 1.85, SD = 1.35]
than those exposed to uncommon symptoms. When five symptoms
were presented, symptom type did not lead to a significant difference
in risk perception [t(69.90) = 0.09, P = 0.93, Mfive-common-APA = 20.19,
SD = 20.77; Mfive-uncommon-APA = 20.64, SD= 19.98] or consultation
intention [t(294)= 0.59, P = 0.57, Mfive-common-APA = 2.00, SD = 1.35;
Mfive-uncommon-APA = 2.19, SD = 1.43].

Discussion
While consumers ’ perceived risk of a disease and engagement
in preventive and remedial actions are likely formed through multiple
sources of influence, this study focused on the effects of exposure to
specific content elements strategically placed in DTC advertising.
Based on the framework of representative heuristic, we suggested
college students ’ exposure to the APA diagnostic guideline has
potential to reduce their perceived lifetime risk of depression and
intention to consult a health professional to discuss depression. The
findings of this study revealed when the ad mentioned a relatively long
list of symptoms, exposure to the diagnostic guideline reduced risk
perception and consultation intention significantly, whereas in the
presence of a short list of symptoms, the APA guideline had minimal
impact.
Putsis and Dhar19 suggested brand promotions produce the
expansion of a new product category in addition to brand switching.
This suggests promotions are not necessarily a zero-sum game.
Donohue and Berndt2 found DTC advertising for antidepressants
increased the number of depression diagnosis and requests for
antidepressant treatment, implying DTC advertising contributed to the
expansion of the antidepressant market. The findings of this study
have implications for how practitioners can use DTC advertising in an
effective and socially responsible way to expand a drug category.
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How can advertising practitioners use DTC advertising to expand
a drug category? From a marketing perspective, one may assume that
including a diagnostic guideline such as the APA guideline regarding
the appropriate diagnosis of clinical depression will always be
detrimental to the growth of a drug category, because it makes the
health problem seem more difficult to develop. This assumption may
present an ethical dilemma for DTC advertising practitioners, because
from the perspective of consumer welfare, presenting a diagnostic
guideline would enable consumers to have more accurate and
balanced information about their health problems.
The current study illuminates how practitioners can resolve this
dilemma by showing that a diagnostic guideline’s capability to reduce
consumer risk perception of a disease was significantly reduced when
the amount of symptom-related information was small. That is, the
guideline significantly reduced consumer risk perception of depression
only when the ad presented a large amount of symptom-related
information. Therefore, when practitioners present a diagnostic
guideline to avoid the criticism that DTC ads omit valuable health
information and therefore offer limited educational value,20 they should
consider reducing the amount of information in the ad about the
symptoms of the health problem.
The findings also have implications for consumer health. If some
content elements of DTC advertising can influence consumers ’
perceived risk of diseases and intention for health-related behaviors,
would the influence contribute to consumer health? To address the
question, we conceptualized the following three possible situations.
Situation 1: Consumers have underrated perception of the
risk of depression, and exposure to the content elements
leads them to have more realistic perception.
Situation 2: Consumers have overrated perception of the risk
of depression, and exposure to the content elements leads
them to have further inflated perception.
Situation 3: Consumers’ perception may be more or less
evenly split around the figures presented by the
epidemiological data, and exposure to the content elements
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may drive risk perception to be either more realistic or
overrated.
The effects may contribute to public health in the first situation,
whereas the second situation may indicate a negative consequence.
Interpreting the third situation is more complex.
Our data for women indicated the first situation, as females
from the control group perceived their lifetime risk to be 20.06 (SD =
15.74) while the real lifetime risk of depression for women is 25
percent.16–17 The data indicated the second situation for men, as males
from the control group perceived their lifetime depression risk to be
17.83 percent (SD = 23.53) while the real lifetime risk of depression
for men is 12 percent.16 –17 For men, therefore, exposure to
combinations of content elements in DTC antidepressant advertising
can drive their perceived lifetime risk of depression to be significantly
more inflated than their actual lifetime risk.
For this reason, some may argue DTC antidepressant
advertising may have negative social consequences among men.
However, depending on the health problem, we suggest the potential
of DTC advertising to produce unrealistically high risk perception may
result in contributing to consumer welfare. For instance, considering
depression is a largely under-treated disease,7 the power of DTC
antidepressant advertising to raise consumer perception of the risk of
depression should be considered as an effective and socially beneficial
means to detect potential depressive patients and encourage them to
seek professional help.

Limitations and Suggestions for Future Research
The current study has a number of limitations. First, this study
is based on a convenient sample of college students. Therefore, the
results may not generalize to college-age people or the general
consumer population. Therefore, future researchers may explore how
the results may be replicated or vary across various segments of the
population (for example, Asian Americans, Hispanic-Americans, versus
white Americans), research settings (for example, laboratory
experiment versus field experiment), and a variety of disease
categories. Second, the experimental stimuli were entirely text-based
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in order for the effective manipulations of the content elements. Even
though similar approaches have been used in previous research,15,21 it
would be meaningful to replicate the findings using more realistic
versions of antidepressant advertisements. Another issue is whether
the findings generalize over a longer period of time.
The study presented the stimulus and immediately measured
risk perception and consultation intention. As Davis and Meader21
suggested, it will be worth exploring if the effects of exposure to the
message elements endure over longer periods of time. Future studies
may also address the possibility that motivation, ability and
opportunity for information processing may change the patterns of
interactions observed, as high-elaboration reduces consumers ’
dependence on heuristic information processing for judgment making.
Therefore, consumers under a high-elaboration condition may be less
subject to the influence of the representativeness heuristic.
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Appendix
Table 1: MANOVA Results for Risk Perception and Consultation Intention

Table 2: Mixed MANOVA Results for Risk Perception and Help-seeking Intention

ws is a within-subjects factor including risk perception and consultation intention.
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